Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2017 Sep;17(3):403-412.
doi: 10.1007/s40268-017-0191-y.

Comparative Effect of Calcium Channel Blockers on Glomerular Function in Hypertensive Patients with Diabetes Mellitus

Yayoi Nishida  1 , Yasuo Takahashi  2   3 , Kotoe Tezuka  1 , Satoshi Takeuchi  4 , Tomohiro Nakayama  5   6 , Satoshi Asai  4
Affiliations
Comparative Study

Comparative Effect of Calcium Channel Blockers on Glomerular Function in Hypertensive Patients with Diabetes Mellitus

Yayoi Nishida et al. Drugs R D. 2017 Sep.

Abstract

Background: We conducted a retrospective cohort study to evaluate and compare the longitudinal effect of monotherapy with L-, L/T-, L/N-, and L/N/T-type calcium channel blockers (CCBs) on estimated glomerular filtration rate (eGFR), and to investigate the association of treatment duration with eGFR in diabetic patients with hypertension.

Methods: Using a clinical database, we identified new users of five CCBs, i.e. amlodipine (L-type, n = 693), nifedipine (L-type, n = 189), azelnidipine (L/T-type, n = 91), benidipine (L/N/T-type, n = 183), and cilnidipine (L/N-type, n = 61). We used a multivariable regression model to evaluate and compare the effects of these drugs on eGFR and serum creatinine, up to 12 months after initiation of study drug administration.

Results: There was no significant association between treatment duration and both eGFR and serum creatinine level with all CCB types. In addition, there was no significant difference in mean change in eGFR among the five CCBs, with any treatment duration.

Conclusions: Our findings suggest that monotherapy with an L-, L/T-, L/N/T-, or L/N-type CCB may have little influence on renal function parameters and may be safely used in hypertensive patients with diabetes.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

Yayoi Nishida, Yasuo Takahashi, Kotoe Tezuka, Satoshi Takeuchi, Tomohiro Nakayama, and Satoshi Asai have no conflicts of interest to declare.

Ethical approval

Statement of Human Rights For this type of study, formal consent is not required.

Figures

Fig. 1
Fig. 1
Adjusted mean percentage change of eGFR (error bar indicates standard error) during each exposure period for five calcium channel blockers (L-type: amlodipine and nifedipine, L/T-type: azelnidipine, L/N/T-type: benidipine, L/N-type: cilnidipine). Data were adjusted for covariates of age, sex, and duration of diabetes mellitus. eGFR estimated glomerular filtration rate
See this image and copyright information in PMC

References

    1. Kidney Disease Outcomes Quality Initiative (K, DOQI) K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(5 Suppl 1):S1–S290. - PubMed
    1. Kidney Disease: Improving Global Outcomes (KDIGO) Management of Blood Pressure Work Group KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2012;2(5):337–414. doi: 10.1038/kisup.2012.46. - DOI
    1. Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH2014) Hypertens Res. 2014;37(4):253–390. doi: 10.1038/hr.2014.20. - DOI - PubMed
    1. Hayashi K, Wakino S, Sugano N, Ozawa Y, Homma K, Saruta T. Ca2+ channel subtypes and pharmacology in the kidney. Circ Res. 2007;100(3):342–353. doi: 10.1161/01.RES.0000256155.31133.49. - DOI - PubMed
    1. Hayashi K, Homma K, Wakino S, Tokuyama H, Sugano N, Saruta T, et al. T-type Ca channel blockade as a determinant of kidney protection. Keio J Med. 2010;59(3):84–95. doi: 10.2302/kjm.59.84. - DOI - PubMed

Publication types